JLP (SPAG9) Antibody (N-term) Blocking peptide

The synthetic peptide sequence used to generate the antibody was selected from the N-term region of human SPAG9. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

[SPAG9; SPAG9; JLP; CT89; HLC4; HLC6; JIP4; PHET; PIG6; HLC-6; JIP-4; HSS; KIAA0516; MAPK8IP4; SYD1; JIP-4; JNK-interacting protein 4; CT89; HLC-6; JLP; PHET]

[C-Jun-amino-terminal kinase-interacting protein 4; C-Jun-amino-terminal kinase-interacting protein 4; C-Jun-amino-terminal kinase-interacting protein 4; sperm associated antigen 9; Cancer/testis antigen 89; CT89; Human lung cancer oncogene 6 protein; HLC-6; JNK-associated leucine-zipper protein; JLP; Mitogen-activated protein kinase 8-interacting protein 4; Proliferation-inducing protein 6; Protein highly expressed in testis; PHET; Sperm surface protein; Sperm-associated antigen 9; Sperm-specific protein; Sunday driver 1]